Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Up 5.29%
As of Monday, July 27, Bicara Therapeutics Inc.’s BCAX share price has surged by 5.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Down 5.25%
As of Friday, July 10, Bicara Therapeutics Inc.’s BCAX share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Michael Rose
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Down 6.60%
As of Wednesday, July 08, Bicara Therapeutics Inc.’s BCAX share price has dipped by 6.60%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Up 5.49%
As of Monday, June 29, Bicara Therapeutics Inc.’s BCAX share price has surged by 5.49%, which has investors questioning if this is right time to sell.Michael Rose
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Up 5.15%
As of Thursday, June 25, Bicara Therapeutics Inc.’s BCAX share price has surged by 5.15%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,780.6 | $252.6 | 52% |
|
| Shares Out (Mil) | 60.7 | 52.3 | 53% |
|
| Institutional Ownership | 97.6% | 92.1% | 75% |
|
| Float (Mil) | 36.7 | 40.2 | 41% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 482 | 455 | 58% |
|
| Price Change (52-week) |
133.6% | 52.9% | 95% |
|
| Growth | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 12 | |
| Current EPS | ($0.825) | ($3.478) | ($3.633) | |
| Month Ago EPS | ($0.825) | ($3.478) | ($3.633) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.678) | ($2.789) | ($3.038) | |
| Year/Year Chg | (10.9%) | 37.9% | 31.3% | |
| Financials | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($157) | ($43) | 8% |
|
| EPS (TTM) | ($2.797) | ($1.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($116) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 13% |
|
| Enterprise Value (Q1) (Mil) | $841 | $180 | 39% |
|
| Valuation | BCAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.46 | 2.56 | 69% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (30.5%) | (49.8%) | 17% |
|
| ROE | (32.3%) | (55.5%) | 19% |
|
| Liabilities to Assets | 7.2% | 30.3% | 4% |
|
| F-Score | 1 | 3 | 1% |
|
Bicara Therapeutics Inc. did not pass any screens on 7/31/2026.
